44
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Differences in immune responses to SARS-CoV-2 in children and adults are linked to clinical outcomes.

          Elucidating immune responses in COVID-19

          Compared to adults, young people with COVID-19 have milder disease. Pierce et al. compared immune responses in hospitalized adult and young patients with COVID-19 to identify potential contributing mechanisms. In the first week after hospitalization, circulating IL-17A and IFN-γ concentrations were inversely related to age. More than 3 weeks later, CD4 + T cell responses to viral spike protein were higher in adult compared to younger patients. Neutralizing antibody titers were also higher in adults and correlated positively with age and negatively with IL-17A and IFN-γ. These findings suggest that the poor outcome in adults is not caused by a failure to generate adaptive immune responses.

          Abstract

          Children and youth infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have milder disease than do adults, and even among those with the recently described multisystem inflammatory syndrome, mortality is rare. The reasons for the differences in clinical manifestations are unknown but suggest that age-dependent factors may modulate the antiviral immune response. We compared cytokine, humoral, and cellular immune responses in pediatric (children and youth, age <24 years) ( n = 65) and adult ( n = 60) patients with coronavirus disease 2019 (COVID-19) at a metropolitan hospital system in New York City. The pediatric patients had a shorter length of stay, decreased requirement for mechanical ventilation, and lower mortality compared to adults. The serum concentrations of interleukin-17A (IL-17A) and interferon-γ (IFN-γ), but not tumor necrosis factor–α (TNF-α) or IL-6, were inversely related to age. Adults mounted a more robust T cell response to the viral spike protein compared to pediatric patients as evidenced by increased expression of CD25 + on CD4 + T cells and the frequency of IFN-γ + CD4 + T cells. Moreover, serum neutralizing antibody titers and antibody-dependent cellular phagocytosis were higher in adults compared to pediatric patients with COVID-19. The neutralizing antibody titer correlated positively with age and negatively with IL-17A and IFN-γ serum concentrations. There were no differences in anti-spike protein antibody titers to other human coronaviruses. Together, these findings demonstrate that the poor outcome in hospitalized adults with COVID-19 compared to children may not be attributable to a failure to generate adaptive immune responses.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: found

          Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

          There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

            Journal of Clinical Investigation
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

              Summary Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development, interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of pandemic control measures. Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively. CD4+ T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The M, spike and N proteins each accounted for 11-27% of the total CD4+ response, with additional responses commonly targeting nsp3, nsp4, ORF3a and ORF8, among others. For CD8+ T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted. Importantly, we detected SARS-CoV-2−reactive CD4+ T cells in ∼40-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2.
                Bookmark

                Author and article information

                Journal
                Sci Transl Med
                Sci Transl Med
                STM
                scitranslmed
                Science Translational Medicine
                American Association for the Advancement of Science
                1946-6234
                1946-6242
                07 October 2020
                : 12
                : 564
                : eabd5487
                Affiliations
                [1 ]Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
                [2 ]Department of Immunobiology, Yale University, New Haven, CT 06520, USA.
                [3 ]Department of Pediatrics, The Children’s Hospital at Montefiore and Albert Einstein College of Medicine, Bronx, NY 10461, USA.
                [4 ]Department of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA.
                [5 ]Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
                [6 ]Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, USA.
                [7 ]Department of Emergency Medicine and Biostatistics, Yale University, New Haven, CT 06520, USA.
                [8 ]Department of Internal Medicine, Yale University, New Haven, CT 06520, USA.
                Author notes
                [*]

                Present address: Hospital for Sick Children (SickKids Research Institute), Toronto ON, Canada.

                []Corresponding author. Email: kevan.herold@ 123456yale.edu (K.C.H.); betsy.herold@ 123456einstein.yu.edu (B.C.H.)
                [‡]

                These authors contributed equally to this work.

                Author information
                http://orcid.org/0000-0001-5041-1412
                http://orcid.org/0000-0001-8940-5423
                http://orcid.org/0000-0003-1491-4156
                http://orcid.org/0000-0001-8172-258X
                http://orcid.org/0000-0001-6281-4833
                http://orcid.org/0000-0003-1409-3554
                http://orcid.org/0000-0002-3119-0869
                http://orcid.org/0000-0002-8129-4033
                http://orcid.org/0000-0002-6253-7298
                http://orcid.org/0000-0001-9968-1587
                http://orcid.org/0000-0003-0232-7077
                http://orcid.org/0000-0001-8953-6183
                http://orcid.org/0000-0003-3699-2446
                http://orcid.org/0000-0003-0417-4000
                http://orcid.org/0000-0003-1534-6613
                http://orcid.org/0000-0001-9974-0786
                Article
                abd5487
                10.1126/scitranslmed.abd5487
                7658796
                32958614
                6b406f22-da43-4c3f-b870-cde6a8efe09b
                Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

                This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 29 June 2020
                : 16 September 2020
                Funding
                Funded by: doi http://dx.doi.org/10.13039/100000002, National Institutes of Health;
                Award ID: UL1 TR001073
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R01AI134367
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R01AI134367
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: T32AI007501
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: P30AI124414
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: U19 AI142777
                Categories
                Research Article
                Research Articles
                STM r-articles
                Medicine
                Coronavirus
                Custom metadata
                Orla Smith
                Sef Rio

                Comments

                Comment on this article